-
公开(公告)号：US20150017265A9
公开(公告)日：2015-01-15
申请号：US12016180
申请日：2008-01-17
Applicant: Eugene T. Michal , Shubhayu Basu , Alexander J. Sheehy , Francis G. Spinale , Rupak Mukherjee
Inventor： Eugene T. Michal , Shubhayu Basu , Alexander J. Sheehy , Francis G. Spinale , Rupak Mukherjee
CPC classification number: A61L27/26 , A61L27/20 , A61L27/22 , A61L27/3834 , A61L27/50 , A61L27/52 , A61L2300/418 , A61L2300/64 , A61L2400/06 , A61L2430/20 , C08L5/04 , C08L89/00
Abstract: A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture.
-
公开(公告)号：US08888675B2
公开(公告)日：2014-11-18
申请号：US12855469
申请日：2010-08-12
Applicant: John J. Stankus , Barbara E. Stamberg , Pamela A. Kramer-Brown , Jesus Magana , Shubhayu Basu , Yuet Mei Khong , Florian N. Ludwig
Inventor： John J. Stankus , Barbara E. Stamberg , Pamela A. Kramer-Brown , Jesus Magana , Shubhayu Basu , Yuet Mei Khong , Florian N. Ludwig
IPC: A61F2/00 , A61N1/362 , A61B17/12 , A61B17/064 , A61F2/24 , A61B17/068
CPC classification number: A61F2/2487 , A61B17/064 , A61B17/068 , A61B17/12122 , A61B17/12181 , A61B17/12186 , A61B17/12195 , A61B2017/0647 , A61L2430/20
Abstract: Apparatus and methods are disclosed for supporting ischemic tissue of the heart using scaffolds that may be placed within the heart percutaneously. A scaffold assembly may include a layer of biocompatible material detachably secured to a placement rod, such that the placement rod may be used to urge the layer of biocompatible material through a catheter to adjacent an area of ischemic tissue. Anchors may secure the layer of material to the myocardium. Multiple layers of biocompatible material may be placed in the ventricle separately to form the scaffold. In some embodiments, a scaffold is formed or reinforced by injecting a polymer, such as a visco-elastic foam, around an inflatable member inflated within a ventricle.
Abstract translation: 公开了用于支持心脏的缺血组织的装置和方法，所述支架可以经皮放置在心脏内的支架。 支架组件可以包括可拆卸地固定到放置杆的生物相容性材料层，使得放置杆可以用于通过导管将生物相容性材料层推动到邻近缺血组织的区域。 锚固体可以将材料层固定到心肌。 可以将多层生物相容性材料分别放置在心室中以形成支架。 在一些实施方案中，通过将聚合物（例如粘弹性泡沫）注射到在心室内膨胀的可充气构件的周围形成或增强支架。
-
23.发明授权Modified two-component gelation systems, methods of use and methods of manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US08741326B2
公开(公告)日：2014-06-03
申请号：US11561328
申请日：2006-11-17
Applicant: Gene Michal , Shubhayu Basu
Inventor： Gene Michal , Shubhayu Basu
CPC classification number: A61K35/28 , A61K33/14 , A61K33/20 , A61K38/1858 , A61K38/363 , A61K38/4833 , A61L27/26 , A61L27/3873 , A61L27/52 , C12Y304/21005 , A61K2300/00 , A61K38/00
Abstract: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof.
Abstract translation: 生物支架可以由不同凝胶化系统的凝胶组分的混合物形成。 例如，生物支架可以通过混合至少两种不同的双组分凝胶化体系的至少两种不同组分形成第一混合物并通过混合至少两种不同组分（构成第一混合物的组分） 的至少两种不同的双组分凝胶化体系以形成第二混合物。 可以将第一混合物或第二混合物中的处理剂如细胞类型或生长因子加入。 在一些实施方案中，处理剂不加入任何混合物中。 可以将第一混合物与第二混合物共注射以在梗塞区域中形成生物支架，用于治疗它们。
-
24.发明授权Multiple growth factor compositions, methods of fabrication, and methods of treatment 失效多重生长因子组合物，制备方法和治疗方法公开(公告)号：US08703180B1
公开(公告)日：2014-04-22
申请号：US11877635
申请日：2007-10-23
Applicant: John J. Stankus , Florian N. Ludwig , Evgenia Mandrusov , Liangxuan Zhang , Hong Ma , Jinping Wan , Shubhayu Basu
Inventor： John J. Stankus , Florian N. Ludwig , Evgenia Mandrusov , Liangxuan Zhang , Hong Ma , Jinping Wan , Shubhayu Basu
CPC classification number: A61K38/30 , A61K9/06 , A61K9/127 , A61K35/34 , A61K38/18 , A61K38/1825 , A61K38/1833 , A61K38/1858 , A61K38/1866 , A61K38/1891 , A61K38/19 , A61K38/193 , A61K38/57 , A61K45/06 , A61L27/3834 , A61L27/52 , A61L27/54 , A61L27/58 , A61L2300/414 , A61L2300/604 , A61L2300/626 , A61L2430/20 , A61K2300/00
Abstract: Disclosed are compositions with sustained-release carriers associated with at least two different types of growth factors and methods of fabrication and treatments thereof. In some embodiments, simultaneous release of the growth factors may be preferred while in other embodiments, sequential release of the growth factors may be preferred. Application of at least two growth factors to an injury site, e.g., compromised cardiac tissue caused by, for example, myocardial infarction or ischemic heart failure, may better mimic and induce the complex growth factor signaling pathways necessary to improve cardiac function. When applied to a patient after a myocardial infarction or ischemic heart failure, multiple growth factors within a sustained-release carrier platform or platforms may cause a synergistic effect on injected cells intending to alleviate left ventricle remodeling. Methods of treatment include percutaneous, sub-xiphoid, and open chest methods using catheters and/or syringes.
Abstract translation: 公开了具有与至少两种不同类型的生长因子相关联的持续释放载体的组合物及其制备和处理方法。 在一些实施方案中，生长因子的同时释放可以是优选的，而在其它实施方案中，生长因子的顺序释放可能是优选的。 至少两个生长因子施加到损伤部位，例如由心肌梗塞或缺血性心力衰竭引起的受损的心脏组织可以更好地模拟和诱导改善心脏功能所必需的复合生长因子信号传导途径。 当在心肌梗死或缺血性心力衰竭后应用于患者时，持续释放载体平台或平台内的多个生长因子可能对旨在减轻左心室重塑的注射细胞产生协同效应。 治疗方法包括使用导管和/或注射器的经皮，亚剑虫和胸部开胸方法。
-
公开(公告)号：US08377033B2
公开(公告)日：2013-02-19
申请号：US12877820
申请日：2010-09-08
Applicant: Shubhayu Basu , Randolf von Oepen , Eugene Michal , Florian Ludwig
Inventor： Shubhayu Basu , Randolf von Oepen , Eugene Michal , Florian Ludwig
IPC: A61M25/00
CPC classification number: A61M25/1011 , A61B17/12045 , A61B17/12122 , A61B17/12136 , A61B17/12186 , A61B17/3478 , A61B2017/00243 , A61B2017/00495 , A61M25/003 , A61M2025/0092 , A61M2025/1052
Abstract: A reinforcement region is formed within the myocardium by introducing a delivery device through a vessel wall to a treatment site within a myocardium. A biomaterial is then delivered to the treatment site as the delivery device is withdrawn from the treatment site to form the reinforcement regions. Formation of the reinforcement region may further include introducing a delivery device through a vessel wall to a region within a myocardium such that the delivery device is positioned within the myocardium substantially parallel to a wall of the myocardium. A biomaterial may be delivered into a space formed within the region by the delivery device. The reinforcement region may be formed around an infarct tissue region of a myocardium to reinforce the damaged tissue.
Abstract translation: 通过将输送装置通过血管壁引导到心肌内的治疗部位，在心肌内形成增强区域。 然后当从处理部位取出输送装置以形成加强区域时，将生物材料输送到处理部位。 加强区域的形成可以进一步包括将输送装置通过血管壁引入心肌内的区域，使得输送装置位于基本上平行于心肌壁的心肌内。 生物材料可以通过输送装置输送到在该区域内形成的空间中。 加强区域可以围绕心肌的梗塞组织区域形成以加强受损组织。
-
Patent Agency Ranking
公开(公告)号：US20120221072A1
公开(公告)日：2012-08-30
申请号：US13405909
申请日：2012-02-27
Applicant: Kiyotaka FUKAMACHI , Alex MASSIELLO , Mariko KOBAYASHI , Ray DESSOFFY , Eugene JUNG , Shubhayu BASU
Inventor： Kiyotaka FUKAMACHI , Alex MASSIELLO , Mariko KOBAYASHI , Ray DESSOFFY , Eugene JUNG , Shubhayu BASU
CPC classification number: A61N1/36114 , A61N1/36139 , A61N1/3627
Abstract: Treatment of heart failure in a patient by electrically modulating both the sympathetic and parasympathetic autonomic cardiac nerve fibers that innervate the patient's heart at an extravascular site in the pericardial space of the heart. The extravascular site is any suitable single location inside the chest cavity that carries both sympathetic and parasympathetic cardiac nerves such as the cardiac plexus or the pericardial transverse sinus or any two separate extravascular sites with one site carrying predominantly sympathetic cardiac nerves and the other site carrying predominantly parasympathetic cardiac nerves for electrically modulating the balance of autonomic cardiac nerve control. Physiologic inputs from a neuromodulation system's own sensors or from separate implanted or external cardiovascular hemodynamic sensor systems can be used for closed loop control over the balance of sympathetic and parasympathetic cardiac autonomic effects on the patient's cardiac function in real time response to chronic and transient physiologic needs.
Abstract translation: 通过电动调节在心脏心包空间内的血管外位置支配患者心脏的交感神经和副交感神经自主神经纤维来治疗患者的心力衰竭。 血管外部位是胸腔内任何合适的单一位置，其携带交感神经和副交感神经，如心脏神经丛或心包横向窦或任何两个分离的血管外部位，一个位点主要携带交感神经，另一个位点主要携带 副交感神经，用于电调节自主神经控制的平衡。 来自神经调节系统的自身传感器或来自分离的植入或外部心血管血液动力学传感器系统的生理输入可用于闭环控制对交感神经和副交感神经心脏自主影响对患者心脏功能的平衡，实时响应慢性和短暂的生理需求 。
-
公开(公告)号：US08221744B2
公开(公告)日：2012-07-17
申请号：US11857878
申请日：2007-09-19
Applicant: Shubhayu Basu , Gene Michal , Florian Ludwig , Jinping Wan , John Stankus
Inventor： Shubhayu Basu , Gene Michal , Florian Ludwig , Jinping Wan , John Stankus
CPC classification number: A61L27/52 , A61L27/20 , A61L27/3604 , A61L27/3641 , A61L27/365 , A61L27/3804 , A61L27/3839 , C08L5/04
Abstract: The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.
Abstract translation: 本发明涉及一种制备细胞相容性藻酸盐凝胶的方法及其在治疗心肌病中的应用。
-
公开(公告)号：US20110077618A1
公开(公告)日：2011-03-31
申请号：US12963397
申请日：2010-12-08
Applicant: Shubhayu Basu , Greg W. Chan
Inventor： Shubhayu Basu , Greg W. Chan
CPC classification number: A61M25/003 , A61M25/00 , A61M25/0032 , A61M25/0084 , A61M25/10
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Abstract translation: 本文公开了治疗心肌梗死后损伤的方法和组合物。 在一些实施方案中，可以制造具有处理剂的载体。 载体可以由生物可蚀塑的缓释物质配制。 然后将所得负载载体悬浮在双组分基质系统的至少一个组分中，用于同时递送至心肌梗死后治疗区域。
-
29.发明申请公开(公告)号：US20080125745A1
公开(公告)日：2008-05-29
申请号：US11978986
申请日：2007-10-29
Applicant: Shubhayu Basu , Greg W. Chan
Inventor： Shubhayu Basu , Greg W. Chan
IPC: A61M25/00
CPC classification number: A61M25/003 , A61M25/00 , A61M25/0032 , A61M25/0084 , A61M25/10
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Abstract translation: 本文公开了治疗心肌梗死后损伤的方法和组合物。 在一些实施方案中，可以制造具有处理剂的载体。 载体可以由生物可蚀塑的缓释物质配制。 然后将所得负载载体悬浮在双组分基质系统的至少一个组分中，用于同时递送至心肌梗死后治疗区域。
-
30.发明申请MODIFIED TWO-COMPONENT GELATION SYSTEMS, METHODS OF USE AND METHODS OF MANUFACTURE 有权改性双组分凝胶系统，使用方法和制造方法公开(公告)号：US20080119385A1
公开(公告)日：2008-05-22
申请号：US11561328
申请日：2006-11-17
Applicant: Gene Michal , Shubhayu Basu
Inventor： Gene Michal , Shubhayu Basu
IPC: A61K38/02 , C07K14/475 , C07K14/78
CPC classification number: A61K35/28 , A61K33/14 , A61K33/20 , A61K38/1858 , A61K38/363 , A61K38/4833 , A61L27/26 , A61L27/3873 , A61L27/52 , C12Y304/21005 , A61K2300/00 , A61K38/00
Abstract: A bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. A treatment agent, such as a cell type or a growth factor, can be added to either the first mixture or the second mixture. In some embodiments, the treatment agent is not added to either mixture. The first mixture can be co-injected with the second mixture to form a bioscaffolding in an infarct region for treatment thereof.
Abstract translation: 生物支架可以由不同凝胶化系统的凝胶组分的混合物形成。 例如，生物支架可以通过混合至少两种不同的双组分凝胶化体系的至少两种不同组分形成第一混合物并通过混合至少两种不同组分（构成第一混合物的组分） 的至少两种不同的双组分凝胶化体系以形成第二混合物。 可以将第一混合物或第二混合物中的处理剂如细胞类型或生长因子加入。 在一些实施方案中，处理剂不加入任何混合物中。 可以将第一混合物与第二混合物共注射以在梗塞区域中形成生物支架，用于治疗它们。
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.023 seconds)
